HPTN 083 Webinar – Give PrEP a Shot!

The HIV Prevention Trials Network (HPTN) has launched a new study, HPTN 083, to evaluate whether injectable cabotegravir (CAB) can safely protect cisgender men who have sex with men (MSM) and transgender women (TGW) who have sex with men from acquiring HIV as well as Truvada, an oral tablet taken daily for HIV prevention, also… Read More

Publication of HPTN 052 Final Results: HIV Treatment Offers Durable Prevention of HIV Transmission in Serodiscordant Couples

The HIV Prevention Trials Network (HPTN) announced that the final results of the HPTN 052 study were published in the New England Journal of Medicine (NEJM). This pivotal study demonstrated that antiretroviral therapy (ART) for HIV infection provides durable and reliable protection against the sexual transmission of the virus from infected men and women to their HIV-uninfected… Read More